Clinical Trials Logo

Tobacco Use clinical trials

View clinical trials related to Tobacco Use.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT03413423 Active, not recruiting - Clinical trials for Acute Coronary Syndrome

Post Acute Cardiac Event Smoking (PACES) Study

Start date: January 29, 2018
Phase: N/A
Study type: Interventional

Summary of the Project : Quitting smoking following acute coronary syndrome (ACS) can reduce mortality up to 50%. However, depression and smoking are highly co-morbid and depressed mood may interfere with cessation and independently predicts mortality. Thus, a single, integrated treatment for both smoking and depression could be highly effective in reducing post-acute coronary syndrome mortality. Behavioral Activation (BA) is a well established treatment for depression and has recently shown promise as a treatment for smoking cessation. The investigators systematically developed an intervention integrating gold standard smoking cessation counseling with existing BA based mood management techniques for post-ACS smokers; Behavioral Activation Treatment for Cardiac Smokers (BAT-CS). Objective: For this R01 the investigators will evaluate the efficacy of using a single, integrated treatment that targets both depressed mood and smoking (BAT-CS).

NCT ID: NCT01892813 Active, not recruiting - Nicotine Dependence Clinical Trials

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

Start date: July 2013
Phase: Phase 3
Study type: Interventional

The project is designed to examine the effectiveness of strategies to increase access to treatment for tobacco use and dependence among rural Veteran smokers. In addition, it will examine whether tailored treatment that is designed to address common comorbid conditions that are related to cigarette smoking enhances success with quitting relative to enhanced standard of care. The investigators hypothesize that participants assigned to the tailored tobacco cessation intervention will report greater cessation rates at six months. The investigators also anticipate more favorable outcomes on measures of depressive symptoms, alcohol use, and body weight.